Healthcare economics of bladder cancer: Cost-enhancing and cost-reducing factors

Current Opinion in Urology

Volumn 18, Issue 5, 2008, Pages 533-539

  Noyes, Katia ^a   Singer, Eric A ^b   Messing, Edward M ^b,c  

^a Departments of Community and Preventive Medicine   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c STRONG MEMORIAL HOSPITAL   (United States)

Author keywords

Bladder cancer; Clinical guidelines; Cost effectiveness; Evidence based medicine; Health economics

Indexed keywords

BLADDER CANCER; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH ECONOMICS; HUMAN; OUTCOME ASSESSMENT; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; BLADDER TUMOR; COST BENEFIT ANALYSIS; ECONOMICS;

COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HUMANS; URINARY BLADDER NEOPLASMS;

EID: 54549119199     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOU.0b013e32830b8910     Document Type: Review

References (48)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58:71-96.
2. Catlin A, Cowan C, Hartman M, Heffler S. National health spending in 2006: a year of change for prescription drugs. Health Aff (Millwood) 2008; 27:14-29.
3. Gold MR, Siegel JE, Russell LB, Weinstein MC. Panel on cost-effectiveness in health and medicine. 1sted. New York: Oxford University Press; 1996.
4. Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW. Methods for the economic evaluation of healthcare programmes. 2nd ed. Oxford: Oxford University Press; 1997.
5. Noyes K, Dick AW, Holloway RG. Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: A randomized clinical-economic trial. Med Decis Making 2004; 24:472-485.
6. Davidoff AJ, Powe NR. The role of perspective in defining economic measures for the evaluation of medical technology. Int J Technol Assess Healthc 1996; 12:9-21.
7. Goossens ME, Rutten-van Molken MP, Vlaeyen JW, van der Linden SM. The cost diary: a method to measure direct and indirect costs in cost-effectiveness research. J Clin Epidemiol 2000; 53:688-695.
8. Mushlin AI, Hall WJ, Zwanziger J, et al. The cost-effectiveness of automatic implantable cardiac defibrillators: results from MADIT. Multicenter Automatic Defibrillator Implantation Trial. Circulation 1998; 97:2129-2135.
9. Luce BR, Elixhauser A. Estimating costs in the economic evaluation of medical technologies. Int J Technol Assess Healthc 1990; 6:57-75.
10. Russell LB. Opportunity costs in modern medicine. Health Aff (Millwood) 1992; 11:162-169.
11. van Hout BA, Al MJ, Gordon GS, Rutten FF. Costs, effects and C/E-ratios alongside a clinical trial. Health Econ 1994; 3:309-319.
12. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of costeffectiveness acceptability curves. Health Econ 2001; 10:779-787.
13. Fenwick E, O'Brien BJ, Briggs A. Cost-effectiveness acceptability curves: facts, fallacies and frequently asked questions. Health Econ 2004; 13:405-415.
14. Neumann PJ, Goldie SJ, Weinstein MC. Preference-based measures in economic evaluation in healthcare. Annu Rev Public Health 2000; 21:587-611.
15. Furlong W, Feeney DH, Torrance GW, et al. Guide to design and development of health state utility instrumentation. Hamilton: McMaster University; 1990.
16. Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ 1986; 5:1-30.
17. Registry TCE. Available from: https://research.tufts-nemc.org/cear/ default. aspx. [cited 2008 4/10/2008]
18. Feenstra TL, Hamberg-van Reenen HH, Hoogenveen RT, Rutten-van Molken MP. Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling study. Value Health 2005; 8:178-190.
19. Stouthard MEA, Essink-Bot ML, Bonsel GJ, et al. Disability weights for diseases in the Netherlands. Rotterdam: Erasmus University; 1997.
20. Van Oers JAM. Health on course? The 2002 Dutch public health status and forecasts report. Bilthoven: National Institute of Public Health and the Environment; 2002.
21. Merseburger AS, Kuczyk MA. The value of bladder-conserving strategies in muscle-invasive bladder carcinoma compared with radical surgery. Curr Opin Urol 2007; 17:358-362.
22. Nagele U, Kuczyk M, Anastasiadis AG, et al. Radical cystectomy and orthotopic bladder replacement in females. Eur Urol 2006; 50:249-257.
23. Stenzl A, Holtl L. Orthotopic bladder reconstruction in women-what we have learned over the last decade. Crit Rev Oncol Hematol 2003; 47:147-154.
24. Porter MP, Penson DF. Health related quality of life after radical cystectomy and urinary diversion for bladder cancer: a systematic review and critical analysis of the literature. J Urol 2005; 173:1318-1322.
25. Porter MP, Wei JT, Penson DF. Quality of life issues in bladder cancer patients following cystectomy and urinary diversion. Urol Clin North Am 2005; 32:207-216.
26. Hall MC, Chang SS, Dalbagni G, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007; 178:2314-2330.
27. Babjuk M, Oosterlinck W, Sylvester R et al. European Association of Urology Guidelines on TaT1 (nonmuscle invasive) bladder cancer. http://www.uro-web.org/nc/professional-resources/guidelines/online/. [Accessed 4 October 2008];
28. Stenzl A, Cowan C, De Santis M, et al. European Association of Urology Guidelines on bladder cancer: muscle invasive and metastatic. http://www.ur-oweb.org/nc/professional-resources/guidelines/online/. [Accessed 4 October 2008]
29. Panel NBC. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Bladder Cancer. 2008 [Accessed 4 October 2008]; V.2.2008: [Available from: http://www.nccn.org/professionals/physician-gls/f- guidelines.asp.
30. Botteman MF, Pashos CL, Redaelli A, et al. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 2003; 21:1315-1330.
31. Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 2004; 171 (6 Pt 1):2186-2190; quiz 435.
32. Madeb RR, Golijanin DJ, Noyes K, et al. Treatment of superficial bladder cancer: Are we practicing evidence-based medicine? Cancer 2008; (in press).
33. Konety BR, Allareddy V. Influence of postcystectomy complications on cost and subsequent outcome. J Urol 2007; 177:280-287; discussion 7.
34. Berrum-Svennung I, Hedelin H, Holmang S. Costs of radical cystectomy. Scand J Urol Nephrol 2005; 39:36-41.
35. Konety BR, Dhawan V, Allareddy V, O'Donnell MA. Association between volume and charges for most frequently performed ambulatory and nonambulatory surgery for bladder cancer. Is more cheaper? J Urol 2004; 172:1056-1061.
36. Augustine A, Hebert JR, Kabat GC, Wynder EL. Bladder cancer in relation to cigarette smoking. Cancer Res 1988; 48:4405-4408.
37. HoweGR, Burch JD, Miller AB, et al. Tobacco use, occupation, coffee, various nutrients, and bladder cancer. J Natl Cancer Inst 1980; 64:701-713.
38. Burch JD, Rohan TE, Howe GR, et al. Risk of bladder cancer by source and type of tobacco exposure: a case-control study. Intl J Cancer 1989; 44:622-628.
39. Brenner DJ, Hall EJ. Computed tomography-an increasing source of radiation exposure. NEJM 2007; 357:2277-2284.
40. Dhar NB, Klein EA, Reuther AM, et al. Outcome after radical cystectomy with limited or extended pelvic lymph node dissection. J Urol 2008; 179:873-878; discussion 8.
41. Huang GJ, Stein JP. Open radical cystectomy with lymphadenectomy remains the treatment of choice for invasive bladder cancer. Curr Opin Urol 2007; 17:369-375.
42. Simon MA, Lokeshwar VB, Soloway MS. Current bladder cancer tests: unnecessary or beneficial? Crit Rev Oncol Hematol 2003; 47:91-107.
43. Svatek RS, Sagalowsky AI, Lotan Y. Economic impact of screening for bladder cancer using bladder tumor markers: a decision analysis. Urologic Oncol 2006; 24:338-343.
44. Schmidbauer J, Marberger M. Recent developments in fluorescence cystoscopy: do novel agents bring a benefit? Curr Opin Urol 2007; 17:347-351
45. Alvarez A, Lokeshwar VB. Bladder cancer biomarkers: current developments and future implementation. Curr Opin Urol 2007; 17:341-346.
46. Australia; Available from: http://www.jstor.org/view/16187598/ap060005/ 06a00070/0. [cited 2008 4/10/08].
47. PE. PE Guidelines. Available from: http://ispor.org/PEguidelines/COUNTRY- SPECIFIC.asp. [cited 4/10/2008]
48. NICE. Available from: http://www.ispor.org/workingpaper/healthscience/ QI.aspNICE. [cited 4/10/2008]